Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Feb;54(2):937-9.
doi: 10.1128/AAC.01261-09. Epub 2009 Dec 7.

High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial

Caroline Barau  1 , Constance Delaugerre, Joséphine Braun, Nathalie de Castro, Valérie Furlan, Isabelle Charreau, Laurence Gérard, Caroline Lascoux-Combe, Jean-Michel Molina, Anne-Marie Taburet
Affiliations
Randomized Controlled Trial

High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial

Caroline Barau et al. Antimicrob Agents Chemother. 2010 Feb.

Abstract

Raltegravir concentrations and human immunodeficiency virus type 1 (HIV-1) RNA levels in semen samples from 10 treatment-experienced HIV-1-infected patients were measured after 24 weeks of raltegravir-based highly active antiretroviral therapy (HAART). Semen and plasma HIV-1 RNA levels were below 100 copies/ml and 50 copies/ml, respectively, in all samples. The median raltegravir concentrations in semen samples (n=10) and in plasma samples (n=9) drawn simultaneously were 345 (range, 83 to 707) ng/ml and 206 (range, 106 to 986) ng/ml, respectively. The median semen-to-plasma ratio of raltegravir concentration was 1.42 (range, 0.52 to 6.66), indicating good although variable levels of drug penetration of raltegravir in the seminal compartment.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
(A) Raltegravir concentrations in plasma and semen samples obtained from 10 HIV-infected patients enrolled in the EASIER-ANRS 138 trial at week 24, 5 hours following drug intake. Semen (grey bars) and plasma (black bars) samples were drawn at 5 h postdosing. A plasma sample from patient 8 was drawn at 9 h postdosing (hatched bars). (B) Individual semen-to-plasma ratios of raltegravir concentrations. The ratio is not calculated for patient 8.
See this image and copyright information in PMC

References

    1. Cao, Y. J., and C. W. Hendrix. 2008. Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment. Clin. Pharmacol. Ther. 83:401-412. - PubMed
    1. Cianfriglia, M., M. L. Dupuis, A. Molinari, A. Verdoliva, R. Costi, C. M. Galluzzo, M. Andreotti, A. Cara, R. Di Santo, and L. Palmisano. 2007. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology 4:17. - PMC - PubMed
    1. Croxtall, J. D., and S. J. Keam. 2009. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs 69:1059-1075. - PubMed
    1. De Castro, N., J. Braun, I. Charreau, G. Pialoux, L. Cotte, C. Katlama, F. Raffi, L. Weiss, J. L. Meynard, Y. Yazdanpanah, C. Delaugerre, I. Madelaine-Chambrin, J. P. Aboulker, and J. M. Molina. 2009. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin. Infect. Dis. 49:1259-1267. - PubMed
    1. Ghosn, J., M. L. Chaix, G. Peytavin, J. L. Bresson, J. Galimand, P. M. Girard, F. Raffi, I. Cohen-Codar, J. F. Delfraissy, and C. Rouzioux. 2008. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. J. Antimicrob. Chemother. 61:1344-1347. - PubMed

Publication types